stockrowAMNEAL PHARMACEUTICALS, INC.
AMRX Healthcare Drug Manufacturers Specialty & Generic
AMNEAL PHARMACEUTICALS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 billion, up 8.05% from fiscal 2024.
- Revenue
- +9.96%
- EPS
- +267.0%
- Free cash flow
- −50.9%
- Total debt
- +23.8%
Quarter to September 2026, against a year earlier
Follow AMRX
Alert me
AMNEAL PHARMACEUTICALS, INC. (AMRX) Revenue
AMNEAL PHARMACEUTICALS, INC.'s revenue for fiscal 2025 was $3.0B, up 8.05% from $2.8B in fiscal 2024. Over the twelve months to 30 September 2026 it was $3.2B. Over the past ten years it has ranged from $860.5M (fiscal 2015) to $3.0B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 6 consecutive fiscal years. AMNEAL PHARMACEUTICALS, INC. ranks 11th of 74 Drug Manufacturers Specialty & Generic companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $3.0B | 8.05% |
| FY2024 | $2.8B | 16.73% |
| FY2023 | $2.4B | 8.20% |
| FY2022 | $2.2B | 5.67% |
| FY2021 | $2.1B | 5.08% |
| FY2020 | $2.0B | 22.51% |
| FY2019 | $1.6B | (2.20%) |
| FY2018 | $1.7B | 60.88% |
| FY2017 | $1.0B | 1.52% |
| FY2016 | $1.0B | 18.33% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $862.7M | 8.35% |
| Jun 2026 | $796.2M | 10.20% |
| Mar 2026 | $722.5M | (11.27%) |
| Dec 2025 | $814.3M | 3.80% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| ELAN Elanco Animal Health Incorporated compare | $5.0B |
| RDY Dr. Reddy's Laboratories Ltd compare | $3.3B |
| AMRX AMNEAL PHARMACEUTICALS, INC. | $3.2B |
| HIMS Hims & Hers Health, Inc. compare | $2.6B |
| ALKS Alkermes plc compare | $1.8B |
| LNTH Lantheus Holdings, Inc. compare | $1.6B |
| SUPN Indivior Pharmaceuticals Inc. compare | $1.4B |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $946.0M |
| LQDA Liquidia Corporation compare | $450.9M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on AMRX
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement